Abstract
Background: Effective SARS-CoV-2 vaccination in patients receiving treatment with B-cell depleting agents is challenging. Information on vaccination responses in these patients are a valuable tool to develop efficient vaccination regimens.
Methods: In this single-center retrospective observational study, we report the humoral and cellular response in 34 patients receiving anti-CD20 antibody treatment for renal immune disease.
Results: After base immunization with SARS-CoV-2-vaccines, 92.0% developed a cellular, 32.4% a humoral response. Humoral immunity correlated with B-cell counts and the timespan between anti-CD20 antibody treatment and vaccination. All patients with > 21/µl B-cells, or > 197 days after treatment showed humoral response.
Conclusions: Adequate timing of SARS-CoV-2-vaccinations after anti-CD20 antibody treatment and CD19 measurements are crucial to generate immunity. Awaiting partial B-cell recovery by postponing regularly scheduled anti-CD20 treatment should be considered in patients with stable immune disease.
Trial registration: This study has been retrospectively registered in the German Clinical Trials Register (DRKS00027049) on 29/10/2021.
Keywords: CD20; COVID-19; Kidney; Rituximab; SARS-CoV-2.
【저자키워드】 COVID-19, rituximab, SARS-CoV-2., kidney, CD20, 【초록키워드】 Treatment, SARS-CoV-2, vaccination, Immunity, immunization, immune, clinical, Patient, disease, SARS-CoV-2 vaccination, anti-CD20, antibody treatment, B-cell, cellular response, cellular, retrospective, B-cells, humoral, CD19, Registered, single-center, regimens, anti-CD20 treatment, renal, develop, generate, receiving, correlated, Adequate, depleting, patients receiving treatment, timespan, vaccination response, 【제목키워드】 antibody, SARS-CoV-2 vaccine, Autoimmune disease, response, Patient, B-cell, renal, receiving, modulating,